Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

The letter specifies violations at its Halol facility, with regards to manufacturing of goods.

FPJ Web DeskUpdated: Friday, December 16, 2022, 07:35 PM IST
article-image
Representational image |

Through an exchange filing, Revital maker Sun Pharma has informed that it has received a warning letter from the US Food and Drug Administration.

The letter specifies violations at its Halol facility, with regards to manufacturing of goods, and contents of the letter will be released to the public soon.

RECENT STORIES

India-US Trade Deal Boosts Stocks, Textile Shares Jump Up To 9%

India-US Trade Deal Boosts Stocks, Textile Shares Jump Up To 9%

Urban Company Raises ₹854 Crore From 59 Anchor Investors Ahead Of IPO; Attracts Major Domestic &...

Urban Company Raises ₹854 Crore From 59 Anchor Investors Ahead Of IPO; Attracts Major Domestic &...

GST Exemption For Aviation Sector To Reduce Training Equipment Expense; 5% Flat Rate On Drones

GST Exemption For Aviation Sector To Reduce Training Equipment Expense; 5% Flat Rate On Drones

Sensex, Nifty Rise Amid Strong Global Cues Backed By US-India Trade Discussions, IT, PSU Bank Lead...

Sensex, Nifty Rise Amid Strong Global Cues Backed By US-India Trade Discussions, IT, PSU Bank Lead...

Kerala State Beverages Corporation Witnesses ₹920.74 Crore Profit In Eleven Days, Rolls Out...

Kerala State Beverages Corporation Witnesses ₹920.74 Crore Profit In Eleven Days, Rolls Out...